Tumor burden seems to correlate with MPF levels, and reduced MPF levels in the sera of patients receiving anti-MSLN immunotoxin SS1P therapy are associated with improved progression-free and overall survival rates [81]. The gene discussed is MSLN; the disease is neoplasm.